| Inaugurating the single-topic conference | |
| Preface | |
| Organization of the symposium | |
| What is accomplished and what is needed | 3 |
| New anti-virals against wild-type and lamivudine-resistant hepatitis B virus | 25 |
| Lamivudine therapy of hepatitis B in Japan | 32 |
| Early detection of lamivudine resistant mutant in chronic hepatitis B patients using a novel sensitive method | 38 |
| New antiviral treatment for chronic hepatitis B | 47 |
| New antiviral therapy : adefovir dipivoxil for HBV | 57 |
| Development of entecavir : superior therapy for the management of chronic hepatitis B viral infection | 63 |
| Therapy of hepatitis B and prevention of hepatocellular carcinoma | 77 |
| Differences of clinical characteristics among Japanese patients with hepatitis B virus genotypes B and C | 84 |
| Establishment of a new hepatitis C virus-lb replicon | |
| Hepatitis C virus replication in cell culture | 108 |
| Characterization of the interferon alpha response against HCV in hepatoma cells | 123 |
| Hepatitis C : development of a ribaviron liver-targeting prodrug | 133 |
| HCV replicon inhibitors : mode of actio and resistance mapping | 140 |
| Interferon treatment not only reduces the risk of hepatocellular carcinoma but also improves mortality in patients with chronic hepatitis C showing biochemical response, especially in patients with advanced liver fibrosis | 157 |
| Favorable outcome of patients with C-viral liver disease treated with interferon | 167 |
| IFN receptor and IFN signals | 176 |
| Management and treatment of hepatitis C | 189 |
| Hepatitis C virus and hepatocellular carcinoma | 199 |
| Randomized trial of post-operative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma and long-term outcome | 209 |
| Roles of antiviral therapy in chronic hepatitis C patients should be different according to the stages of liver disease progression | 219 |
| Significance of sustained inflammation in the development of HCC from HCV-associated cirrhotic patients and the prevention of HCC by anti-inflammatory agents | 229 |
| Chemoprevention of hepatocellular carcinoma with retinoid | 241 |
| Vitamin K[subscript 2] administration improves the prognoses of patients with hepatocellular carcinoma presenting high levels of serum des-[gamma]-carboxy prothrombin | 249 |
| Combination chemotherapy for advanced hepatocellular carcinoma | 251 |
| Combined intra-arterial 5-flourouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches | 258 |
| Liver transplantation for hepatitis B virus-related liver disease | 273 |
| Living donor liver transplantation for hepatitis B and C cirrhosis | 283 |
| Living donor liver tranplantation for HBV/HCV-related diseaeses | 293 |
loading...